Results 71 to 80 of about 24,117 (172)

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers

Frontiers in Pharmacology, 2019
Memantine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist utilized as a palliative cure for Alzheimer’s disease. This is the second study examining the memantine concentrations in cerebrospinal fluid.
Martin Valis, David Herman, David Herman, Nela Vanova, Nela Vanova, Jiri Masopust, Jiri Masopust, Oldrich Vysata, Jakub Hort, Jakub Hort, Zbysek Pavelek, Blanka Klimova, Kamil Kuca, Jan Misik, Jan Misik, Jana Zdarova Karasova, Jana Zdarova Karasova   +16 more
doaj   +1 more source

Transdiagnostic patterns of electroencephalography (EEG)‐derived aperiodic activity across schizophrenia‐spectrum, bipolar, and depressive disorders: A systematic review

Psychiatry and Clinical Neurosciences, EarlyView.
Aperiodic electroencephalographic activity is proposed as a scalable marker of cortical population dynamics relevant to excitation–inhibition balance. However, it remains unclear whether aperiodic parameters represent disorder‐specific abnormalities or context‐sensitive indices of clinically relevant brain states.
Gia Han Le, Sabrina Wong, Sara Di Luch, Diana K. Orsini, Shreya Vasudeva, Sri Mahavir Agarwal, Cristian‐Daniel Llach, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Schematic representation of memantine and NMDA receptor.

, 2013
Schematic representation of memantine and NMDA receptor.
W. Ted Brown (167450), Xiaohong Li (71964), Hongen Wei (323077), Mazhar Malik (323081), Ashfaq M. Sheikh (323080), Carl Dobkin (323079)   +5 more
core   +1 more source

Astrocytic EAAT‐2 Upregulation Supports Neuro‐Axonal Homeostasis in Chronic Inflammatory CNS Lesions

Glia, Volume 74, Issue 12, December 2026.
Inflammatory CNS lesions increase extracellular glutamate. Astrocytic EAAT regulation controls glutamate clearance, stabilizes axonal Ca2+ homeostasis, and determines neurite survival during chronic neuroinflammation. ABSTRACT Neuronal loss in multiple sclerosis (MS) is a key factor in the progression of disability.
Luise Reukauf, Anca Margineanu, Bakhrom Muinjonov, Jessy Chen, Yiqin Cui, Kamil Rosiewicz, Helena Radbruch, Ian Munro, Marlen Alisch, Volker Siffrin   +9 more
wiley   +1 more source

Key Binding Interactions for Memantine in the NMDA Receptor

, 2016
Memantine (Namenda) is prescribed as a treatment for moderate to severe Alzheimer’s Disease. Memantine functions by blocking the NMDA receptor, but the key binding interactions between drug and receptor are not fully elucidated.
Henry A. Lester (201363), Walrati Limapichat (1989778), Dennis A. Dougherty (1319310), Wesley Y. Yu (1989784), Emma Branigan (1989781)   +4 more
core   +1 more source

Is Memantine a Potential Therapeutic for Rett Syndrome? [PDF]

, 2013
Memantine is a low-affinity voltage-dependent non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is classified as a neuroprotective aminoadamantane.
Christopher eChapleau, Olivia Bello, Kelsey Blair, Kelsey eBlair, Olivia eBello, Jennifer eLarimore, Christopher Chapleau, Jennifer L. Larimore   +7 more
core   +1 more source

Development and Validation of a Simple UV–HPLC Method to Quantify the Memantine Drug Used in Alzheimer’s Treatment

Pharmaceuticals
Memantine, a non-competitive NMDA receptor antagonist, is used to treat Alzheimer’s disease. Therefore, loading memantine in nanoparticles (NPs) could be an essential tool to improve the treatment effectiveness while reducing drug toxicity.
Débora Nunes, Tânia G. Tavares, Frenacisco Xavier Malcata, Joana A. Loureiro, Maria Carmo Pereira   +4 more
doaj   +1 more source

Effect of Renal Impairment on the Pharmacokinetics of Memantine

Journal of Pharmacological Sciences, 2012
The effect of renal impairment on the pharmacokinetics of a single oral dose of memantine (10 mg) was determined in Japanese subjects. Subjects were assigned to four groups based on baseline creatinine clearance (CLCR): normal renal function (> 80 mL/min,
Takashi Moritoyo, Tomoko Hasunuma, Kazuhiro Harada, Tomonori Tateishi, Makoto Watanabe, Tsutomu Kotegawa, Masahiro Nagai, Yuji Kumagai, Tomomichi Fujitani, Takahumi Okura, Tomikazu Fukuoka, Kenichi Miyoshi, Bunzo Matsuura, Shinya Furukawa, Tomoe Kobori, Hiroyoko Moritoyo, Noriko Nishikawa, Tomoaki Tsujii, Hirotaka Iwaki, Masahiko Nakamura, Satoshi Makino, Kei Ohnuma, Koichiro Yuji, Megumi Hashimoto, Masaru Takasu, Yutaka Hashizume, Koji You, Tomoko Matsumura, Yuji Tanaka, Nahoko Matsumoto, Junichi Nakamura, Jun Miura, Tadao Akizawa, Kozo Kitazawa, Takanori Shibata, Aki Kuroki, Hirokazu Honda, Masanori Mukai, Kyoichi Ohashi, Takuya Morimoto, Hiromitsu Imai, Toshiaki Okudaira, Fuminori Sato, Junko Imanaga, Katsuhiro Tanaka, Masahiro Nomoto   +45 more
doaj   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He, Jingjing Zeng, Guoqing Wang, Yuxin Li, Feng Zhang   +4 more
wiley   +1 more source

Those Debating Alzheimer Disease Modifying Therapies Should Review the Seminal JAGS Dementia Minimal Clinically Important Difference Article

Journal of the American Geriatrics Society, EarlyView.
Frank J. Molnar
wiley   +1 more source